Clark Ian T reported grant involving 5,093 shares of Kyverna Therapeutics, Inc. at $0.00 for $0 on May 27, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Director
DIR
Filed May 29, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$0Shares × reported price
Shares traded
5,093Common Stock
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
21,727Direct
Trade date
May 27, 2026Grant
Filed
May 29, 2026, 4:30 PM ET2-day reporting delay
Accession
0001193125-26-248435Code A · Transaction 95992
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Related trades are temporarily unavailable. Open the SEC filing for the complete report, or reload this page.

KYTX price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
KYTX · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +5.5%1w ago +0.6%1d ago +1.1%
Returns since7d −12%30d −0.9%90d180d1y

Footnotes in full

F1: Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. F2: All of the shares subject to the option shall be fully vested and exercisable on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.